Welcome to our dedicated page for Sangamo Therapeutics SEC filings (Ticker: SGMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sangamo Therapeutics, Inc. (SGMO) SEC filings page on Stock Titan provides direct access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI‑generated summaries that help explain their contents. Sangamo is a genomic medicine company listed on the Nasdaq Capital Market, and its filings document clinical, regulatory, financial and listing‑related developments across its Fabry disease and neurology‑focused pipeline.
Investors can review Sangamo’s current reports on Form 8‑K, which the company uses to report material events. Recent 8‑Ks describe positive topline and updated data from the registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST‑920) in Fabry disease, including mean annualized estimated glomerular filtration rate (eGFR) slopes and safety findings, as well as the FDA’s agreement to use eGFR slope as an endpoint for an accelerated approval pathway. Other 8‑Ks cover quarterly financial results, collaboration and license agreements, executive transitions and a Nasdaq notice granting additional time to regain compliance with the minimum bid price requirement.
Annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available in the feed) provide more detailed information on Sangamo’s research and development expenses, general and administrative costs, cash and cash equivalents, and risk factors related to its genomic medicine programs, collaborations and capital needs. These filings also elaborate on the company’s description of its business as a neurology‑focused genomic medicine company and its reliance on investigational product candidates such as ST‑920, ST‑503 and ST‑506.
On this page, Stock Titan’s tools surface new SGMO filings from EDGAR in near real time and apply AI‑powered analysis to highlight key points, such as clinical endpoints referenced in 8‑Ks, updates on BLA preparation activities, or disclosures about Nasdaq listing compliance. Users can also locate proxy statements and other governance‑related documents to better understand Sangamo’s executive compensation plans and board‑level decisions, as referenced in its SEC filings. This combination of source documents and AI summaries is intended to make it easier to interpret complex regulatory language without replacing the need to read the original filings.
Sangamo Therapeutics’ principal financial officer, Prathyusha Duraibabu, reported an automatic share withholding tied to restricted stock vesting. On January 22, 2026, 36,676 shares of common stock were surrendered to the company at $0.3985 per share to cover mandatory tax withholding on a vested restricted stock unit (RSU) grant. This is treated as a disposition to the issuer for reporting purposes but was not a discretionary sale in the open market.
After this tax withholding event, the officer beneficially owned 660,042 shares of common stock, including shares underlying multiple RSU grants that vest over time, subject to continued service under the company’s 2018 Equity Incentive Plan.
Sangamo Therapeutics executive Scott B. Willoughby, SVP, Chief Legal Officer and Secretary, reported a routine share disposition tied to equity compensation. On January 22, 2026, 36,676 shares of common stock were surrendered to Sangamo solely for mandatory tax withholding on a restricted stock unit (RSU) vesting, using the company’s closing stock price of $0.3985 per share. This is treated as a disposition to the issuer for reporting purposes but was not a discretionary trade in the open market.
After this transaction, Willoughby beneficially owned 665,410 shares of common stock. This amount includes 52,387 shares from the January 22, 2026 vesting of a January 22, 2024 RSU grant, 4,008 RSU shares scheduled to vest quarterly through February 24, 2026, and 120,000 RSU shares from a February 25, 2025 grant that will vest beginning February 25, 2026, subject to continued service and potential acceleration under the company’s 2018 Equity Incentive Plan.
Sangamo Therapeutics president and CEO Sandy Macrae reported a Form 4 transaction involving company common stock. On January 22, 2026, 102,950 shares were automatically surrendered at a price of $0.3985 per share to cover mandatory tax withholding tied to the vesting of restricted stock units under Sangamo’s 2018 Equity Incentive Plan. This is treated as a disposition to the company for reporting purposes but was not a discretionary open-market trade. After this tax-withholding event, Macrae beneficially owned 1,946,584 shares of Sangamo common stock, including multiple RSU grants that continue to vest over time, subject to ongoing service conditions.
Sangamo Therapeutics reported an insider equity transaction by Davis Gregory D, its Head of Research & Technology. On January 22, 2026, a portion of his restricted stock units vested and 7,721 shares of common stock were surrendered solely to cover mandatory tax withholding at a price of
After this tax withholding event, he beneficially owns 191,062 shares of common stock, including vested and unvested RSUs and 5,000 shares previously acquired through the 2020 Employee Stock Purchase Plan. The filing notes this is a required tax withholding transaction and not a discretionary open-market sale.
Sangamo Therapeutics, Inc. reported an insider equity transaction by SVP and Chief Development Officer Nathalie Dubois-Stringfellow. On January 22, 2026, 36,676 shares of common stock were surrendered at $0.3985 per share to cover mandatory tax withholding on a vesting restricted stock unit (RSU) grant, under the company’s 2018 Equity Incentive Plan. This is treated as a disposition to the company for reporting purposes but was not a discretionary open-market trade.
Following this tax withholding event, Dubois-Stringfellow beneficially owned 693,128 shares of Sangamo common stock. This total includes previously vested RSUs, unvested RSUs that will vest over time if service continues, and shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Sangamo Therapeutics officer and Principal Accounting Officer reported an automatic share disposition related to restricted stock units. On November 24, 2025, 578 shares of common stock were surrendered to the company solely to cover mandatory tax withholding on a vesting RSU grant, using the issuer's closing stock price of $0.4166 per share. This is treated as a disposition to the issuer for reporting purposes but is not a discretionary open-market trade.
After this transaction, the reporting person beneficially owned 245,717 shares, including shares from multiple RSU grants that vest over time through February 24, 2026 and beyond, subject to continued service and the terms of the company’s 2018 Equity Incentive Plan.
Sangamo Therapeutics (SGMO) filed a Form 4 for its SVP, Chief Legal Officer and Secretary, reporting an automatic share withholding tied to restricted stock units (RSUs). On November 24, 2025, 2,035 shares of common stock were surrendered to the company solely to cover mandatory tax withholding, using a closing stock price of $0.4166 per share. After this tax transaction, the reporting person beneficially owned 702,086 shares.
The filing explains that these holdings include multiple RSU grants with scheduled vesting through early 2027, all conditioned on continued service. This transaction is characterized as required tax withholding and not a discretionary trade in the open market.
Sangamo Therapeutics (SGMO) reported an insider equity transaction involving its President, CEO and Director. On November 24, 2025, the executive had 7,488 shares of common stock withheld and treated as disposed of at $0.4166 per share to cover mandatory tax obligations tied to a restricted stock unit (RSU) vesting event under the company’s 2018 Equity Incentive Plan. This was not an open-market or discretionary sale.
Following this tax withholding, the executive beneficially owned 2,049,534 shares, including multiple RSU grants that vest over time, such as shares from a February 24, 2023 grant, a January 22, 2024 grant vesting in equal quarterly installments through January 22, 2026, and a February 25, 2025 grant with vesting starting February 25, 2026. All RSU vesting remains contingent on continued service and potential acceleration provisions under the plan.
Sangamo Therapeutics, Inc. executive share transaction disclosure
Sangamo Therapeutics' principal financial officer reported an automatic share transaction related to restricted stock units. On November 24, 2025, 2,544 shares of common stock were surrendered to the company at $0.4166 per share to cover mandatory tax withholding when a portion of a restricted stock unit (RSU) award vested. This is recorded as a disposition to the issuer for reporting purposes but was not a discretionary open-market trade.
After this tax withholding event, the officer beneficially owned 696,718 shares of common stock, including multiple RSU grants that continue to vest over time, subject to continued service and potential acceleration under the company’s 2018 Equity Incentive Plan.
Sangamo Therapeutics (SGMO) reported a routine insider equity transaction by its SVP-Chief Development Officer on a Form 4. On November 24, 2025, the officer surrendered 2,544 shares of common stock at $0.4166 per share solely to cover mandatory tax withholding on a vesting restricted stock unit (RSU) grant under the company’s 2018 Equity Incentive Plan. This withholding is treated as a disposition to the company for reporting purposes but is not a discretionary open-market trade.
Following this tax withholding event, the officer beneficially owned 719,804 shares of common stock. The explanation notes ongoing RSU vesting schedules from grants made in February 2023, January 2024, and February 2025, all subject to continued service and potential acceleration as provided in the equity plan.